Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)

Next Previous
Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegipanermin (Primary) ; Remdesivir
  • Indications COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Sponsors INmune Bio

Most Recent Events

  • 16 Feb 2022 Status changed from recruiting to discontinued.
  • 04 Aug 2021 According to an INmune Bio media release, data from this trial should be delivered to the Data Safety Monitoring Board this month.
  • 05 May 2021 According to an INmune Bio media release, the company continued to advance this Phase 2 trial of Quellor toward a go/no-go decision by the DSMB around mid-year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top